[Form 4] Beyond Air, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Beyond Air, Inc. (XAIR) reported an insider equity change for a director on Form 4. On November 4, 2025, the Board approved an option repricing effective that same day, reducing the exercise price of multiple stock option grants to $1.95 per share, which matches the closing price of Beyond Air’s common stock on November 3, 2025.

The filing shows that previously granted stock options with higher exercise prices, including options priced at $10.80 and $5.892 per share, were adjusted to the new $1.95 level. All other terms of the options, such as the number of underlying shares and expiration dates, remain unchanged.

The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan. They continue to vest according to the original vesting schedules set out in the award agreements, contingent on the reporting person’s continued service with Beyond Air on the applicable vesting dates.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Yoori

(Last) (First) (Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY NY 11530

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			2,250	(2)	(2)	Common Stock	2,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		2,250		(2)	(2)	Common Stock	2,250	(1)	2,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			2,000	(2)	(2)	Common Stock	2,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		2,000		(2)	(2)	Common Stock	2,000	(1)	2,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,500	(2)	(2)	Common Stock	1,500	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,500		(2)	(2)	Common Stock	1,500	(1)	1,500	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			750	(2)	(2)	Common Stock	750	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		750		(2)	(2)	Common Stock	750	(1)	750	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$5.892	11/04/2025		D(1)			3,750	(2)	(2)	Common Stock	3,750	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		3,750		(2)	(2)	Common Stock	3,750	(1)	3,750	D

Explanation of Responses:

1. On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.

2. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Yoori Lee	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Beyond Air (XAIR) report on this Form 4?

The Form 4 reports that a director of Beyond Air, Inc. had previously granted stock options repriced on November 4, 2025, with the exercise price reduced on multiple option grants.

What new exercise price applies to the repriced Beyond Air (XAIR) stock options?

The exercise price of the director’s stock options was reduced to $1.95 per share, which equals the closing price of Beyond Air’s common stock on November 3, 2025.

Which Beyond Air stock option grants were affected by the repricing?

The filing lists multiple stock options (right to buy) that were originally granted at higher exercise prices such as $10.80 and $5.892 per share, all reset to $1.95 per share on November 4, 2025.

Did the Beyond Air option repricing change vesting or other terms of the awards?

No. The filing states that all other terms of the options remain unchanged, and the awards continue to vest under the original vesting schedules, subject to the reporting person’s continued service with the company.

Under which plan were the repriced Beyond Air (XAIR) stock options granted?

The stock option award was issued under Beyond Air’s Amended and Restated 2013 Equity Incentive Plan, as amended, and follows the vesting terms previously reported for those awards.

Is this Beyond Air Form 4 filed for one or multiple reporting persons?

The Form 4 is indicated as filed by one reporting person, reflecting the transactions of a single director related to their stock option grants.

What is the significance of the November 4, 2025 date in this Beyond Air filing?

November 4, 2025 is both the earliest transaction date and the effective date of the Board-approved option repricing described in the Form 4.